Literature DB >> 1683501

Acromegaly due to ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumour. Dynamic hormonal responses to various stimuli.

M Glikson1, I Gil-Ad, E Galun, R Dresner, S Zilberman, Y Halperin, E Okon, Z Laron, A Rubinow.   

Abstract

Ectopic GHRH is a relatively uncommon cause of acromegaly, which should be differentiated from pituitary adenoma, in order to avoid damage to the pituitary gland from unnecessary interventions. We report here on a 66-year-old man with acromegaly due to a GHRH-secreting bronchial carcinoid tumour, who recovered completely following removal of the tumour. His hormonal status was studied before and after the operation. Basal GH, GHRH, IGF-I and PRL levels, as well as plasma GH response to glucose load and TRH administration were abnormal before the operation, and became normal thereafter. The somatostatin analogue SMS 201-995 was found to be a potent inhibitor of the ectopic GHRH and the GH secretion (greater than 500 to 42 ng/l and 15.4 micrograms/l to 0.8 microgram/l, respectively). The effect on GHRH proved to be due to direct effect of somatostatin on the tumour cells, as demonstrated in tissue culture studies. A mixed meal was found immediately to suppress GHRH levels without such an effect on GH secretion. We conclude that the neuroendocrine tests usually practised in acromegaly cannot differentiate between ectopic GHRH secretion and pituitary adenoma. High plasma GHRH levels may serve as a diagnostic test for excessive GHRH production, which is almost always ectopic. These high levels are suppressible by somatostatin and a mixed meal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683501     DOI: 10.1530/acta.0.1250366

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  5 in total

Review 1.  Ectopic secretion of growth hormone-releasing hormone in man.

Authors:  M Losa; J Schopohl; K von Werder
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

Review 2.  Ectopic acromegaly due to growth hormone releasing hormone.

Authors:  Ali A Ghazi; Alireza Amirbaigloo; Azizollah Abbasi Dezfooli; Navid Saadat; Siavash Ghazi; Marina Pourafkari; Farrokh Tirgari; Dheepti Dhall; Serguei Bannykh; Shlomo Melmed; Odelia Cooper
Journal:  Endocrine       Date:  2012-09-15       Impact factor: 3.633

3.  Molecular challenges of neuroendocrine tumors.

Authors:  Parthik Patel; Karina Galoian
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

4.  Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone.

Authors:  I Gil-Ad; B Klinger; A Pertzelan; B Erster; A Silbergeld; H Talpaz; Z Laron
Journal:  J Endocrinol Invest       Date:  1992-11       Impact factor: 4.256

5.  Ectopic growth hormone-releasing hormone secretion by a neuroendocrine tumor causing acromegaly: long-term follow-up results.

Authors:  Neşe Colak Ozbey; Yersu Kapran; Alp Bozbora; Yeşim Erbil; Cemil Tascioglu; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.